Janney Montgomery Scott LLC Has $9.15 Million Position in Haleon PLC Sponsored ADR (NYSE:HLN)

Janney Montgomery Scott LLC grew its holdings in shares of Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) by 4.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 889,394 shares of the company's stock after buying an additional 38,831 shares during the period. Janney Montgomery Scott LLC's holdings in Haleon were worth $9,152,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Wellington Management Group LLP increased its stake in shares of Haleon by 67.5% during the fourth quarter. Wellington Management Group LLP now owns 15,328,325 shares of the company's stock valued at $146,232,000 after acquiring an additional 6,175,835 shares during the period. Point72 Asset Management L.P. acquired a new position in shares of Haleon during the fourth quarter valued at approximately $45,110,000. Raymond James Financial Inc. acquired a new position in shares of Haleon during the fourth quarter valued at approximately $42,193,000. FMR LLC increased its stake in shares of Haleon by 3.7% during the fourth quarter. FMR LLC now owns 108,827,814 shares of the company's stock valued at $1,038,217,000 after acquiring an additional 3,909,545 shares during the period. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Haleon during the fourth quarter valued at approximately $39,628,000. Institutional investors own 6.67% of the company's stock.

Analyst Ratings Changes

Several research analysts have issued reports on HLN shares. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Haleon in a research report on Monday, March 3rd. HSBC restated a "hold" rating on shares of Haleon in a research report on Wednesday, March 5th. BNP Paribas Exane upgraded shares of Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 price target on the stock in a research report on Tuesday, May 27th. Barclays restated an "overweight" rating on shares of Haleon in a research report on Tuesday, May 6th. Finally, BNP Paribas upgraded shares of Haleon to a "strong-buy" rating in a research report on Tuesday, May 27th. Five investment analysts have rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Haleon currently has a consensus rating of "Moderate Buy" and a consensus price target of $12.33.

Haleon Stock Performance

Haleon stock traded down $0.06 on Friday, reaching $10.40. 14,895,917 shares of the stock were exchanged, compared to its average volume of 9,121,184. The stock has a market cap of $46.77 billion, a PE ratio of 26.65, a PEG ratio of 2.96 and a beta of 0.31. The company has a current ratio of 0.98, a quick ratio of 0.78 and a debt-to-equity ratio of 0.53. Haleon PLC Sponsored ADR has a twelve month low of $8.25 and a twelve month high of $11.42. The firm has a fifty day moving average price of $10.69 and a two-hundred day moving average price of $10.10.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.